Pomerantz LLP Investigates HCA Healthcare Securities Claims After $400 Million Guidance Cut

Pomerantz LLP is investigating securities fraud claims on behalf of investors of HCA Healthcare, Inc., the firm said on October 20, 2026. The investigation concerns whether HCA and certain of its officers or directors engaged in securities fraud or other unlawful business practices, according to the announcement published by GlobeNewswire.

Pomerantz's HCA Investigation and the July Guidance Cut

Pomerantz said investors should contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation follows HCA's July 14, 2026 press release reporting preliminary financial and operating results for the second quarter of 2026. HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in its payer mix that impacted revenue by approximately $400 million in the quarter. On that news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.

HCA Healthcare operates hospitals and other healthcare facilities. The company opened its freestanding emergency department HCA Florida ER-Alico in Lehigh Acres, Florida, on October 20, 2026, a $22 million project with 11 exam rooms and advanced diagnostics including CT and ultrasound, according to Becker's Hospital Review. Chase Christianson was named CEO of HCA Houston Healthcare Kingwood, a 451-bed Texas hospital, effective October 12, 2026, Becker's reported.

Pomerantz's Litigation Record

Pomerantz is a 90-year-old U.S. plaintiffs' securities litigation law firm that represents institutional and individual investors in securities fraud class actions on a contingency fee basis, according to akta.pro company records. The firm secured final approval of a $70 million settlement in the Wynn Resorts securities class action in January 2025, the largest securities class action settlement concerning #MeToo-related allegations. It achieved a $40 million settlement in the Emergent BioSolutions securities class action in February 2025, following four years of litigation as Lead Counsel. The same records list a $3 billion settlement in In re Petrobras Securities Litigation in January and February 2018, achieved as sole lead counsel.

Earlier Pomerantz Investigations

Pomerantz announced on September 3, 2026, that it was investigating L3Harris Technologies for potential securities fraud, following CEO Christopher Kubasik's immediate step-down on August 17, 2026, which caused the stock to fall 4.61% to $278.38, according to Gurufocus. The firm said the same day it was investigating EyePoint, Inc. after its Phase 3 trial for DURAVYU failed to meet visual acuity targets, causing its stock to drop 66.98% to $4.87. Pomerantz also announced on July 30, 2026, an investigation of Metropolitan Bank Holding Corp. over potential securities fraud, according to PR Newswire.

What Comes Next for HCA Investors

Pomerantz's October 20, 2026 announcement advises investors to contact Danielle Peyton about the HCA investigation. The firm's website, pomlaw.com, carries information about joining the class action.